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Aims: The hospitalization of patients with MI has decreased during global lockdown due to the COVID-19
pandemic. Whether this decrease is associated with more severe MI, e.g. MI-CS, is unknown. We aimed to
examine the association of Corona virus disease (COVID-19) pandemic and incidence of acute myocardial
infarction with cardiogenic shock (MI-CS).
Methods: On March 11, 2020, the Danish government announced national lock-down. Using Danish
nationwide registries, we identified patients hospitalized with MI-CS. Incidence rates (IR) and incidence
rate ratios (IRR) were used to compare MI-CS before and after March 11 in 2015–2019 and in 2020.
Results: We identified 11,769 patients with MI of whom 696 (5.9%) had cardiogenic shock in 2015–2019.
In 2020, 2132 MI patients were identified of whom 119 had cardiogenic shock (5.6%). The IR per 100,000
person years before March 11 in 2015–2019 was 9.2 (95% CI: 8.3–10.2) and after 8.9 (95% CI: 8.0–9.9). In
2020, the IR was 7.5 (95% CI: 5.8–9.7) before March 11 and 7.7 (95% CI: 6.0–9.9) after. The IRRs comparing
the 2020-period with the 2015–2019 period before and after March 11 (lockdown) were 0.81 (95% CI:
0.59–1.12) and 0.87 (95% CI: 0.57–1.32), respectively. The IRR comparing the 2020-period during and
before lockdown was 1.02 (95% CI: 0.74–1.41). No difference in 7-day mortality or in-hospital manage-
ment was observed between study periods.
Conclusion: We could not identify a significant association of the national lockdown on the incidence of
MI-CS, along with similar in-hospital management and mortality in patients with MI-CS.
 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the outbreak of Corona virus disease (COVID-19) and
subsequent national lockdown, a concerning ~40% reduction in
acute myocardial infarction (MI) has been reported [1–4], along
with a delay in presentation to hospital compared to before the
COVID-19 era [5]. Professional societies have expressed concern
that patients with relevant symptoms of MI do not present to the
hospital system or that patients present too late. Hence, the
COVID-19 pandemic lockdown has been associated with a lower
incidence of MI hospitalizations, but whether this in turn is associ-
ated with more severe hemodynamic deranged MI, e.g. MI with
cardiogenic shock (MI-CS), is unknown. The impact of the
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mented in only one prior single-centre study from Hong Kong with
a limited number of patients [6].
The leading cause of death in MI is cardiogenic shock with an
in-hospital mortality reaching 40–50% [7–9]. The improved pre-
hospital diagnosis and referral to immediate invasive revascular-
ization has led to a decrease in incidence and mortality of cardio-
genic shock during the last decade [7,8]. Treatment
recommendations for MI with and without cardiogenic shock is
unaffected by the global lockdown [10], so potential aetiologies
to the decrease in MI could be a misguided consideration to the
health care system, a fear of contracting COVID-19 at hospital, or
even a misdiagnosis of MI in the mist of COVID-19 [11]. Delayed
or even missed diagnosis of MI leads to increased morbidity and
mortality, hereunder a suspected increased risk of cardiogenic
shock.
The aim of this study was to examine the incidence of MI-CS
during the COVID-19 era (January 9–May 13, 2020) compared with
a corresponding control period (January 8–May 13, 2015–2019).2. Methods
2.1. Design and setting
In Denmark, the first COVID-19 positive patient was found
February 27, 2020, and on March 11, the national government
announced national lock-down in order to limit spread of infection
(e.g. social distancing, closed borders, schools, day-cares, and
workplaces). Moreover, the national health care system was re-
organized with relocation of resources from non-critical functions
to emergency rooms and intensive care units.
Using data from nationwide Danish registries [12], we con-
ducted this nationwide cohort study. The National Health Services
provides tax-supported healthcare with equal availability unaf-
fected by socioeconomic status [12]. All Danish citizens are
assigned a unique personal identifier code at birth or immigration,
which allows cross linkage of data from registries at an individual
level [13].2.2. Study population and outcome
With use of the Danish Civil Population Registry we included
the entire Danish population as the study population in a com-
bined period from January 8 through May 13, 2015–2019 (control
period) and in the COVID-19 era from January 9 through May 13,
2020. The calendar period was chosen based on 6 periods in 3-
week intervals with 3 periods on each side of the lockdown date
March 11. The accumulation of data within 3 weeks was necessary
due to the small number of patients with MI-CS. We included
2015–2019 years as the control period since the number of
patients with MI-CS in the year 2019 was markedly different com-
pared with the 4 preceding years.
The Danish Civil Population Registry was established in 1968
and contains information on date of birth, sex, residence, immigra-
tion, and vital status, with daily updates [13]. The total length of
follow-up was 126 days for every period, and due to leap year in
2020 the end dates differed between study periods. The study pop-
ulation consisted of persons alive and 18 years at index date (Jan-
uary 8, 2015–2019 and 2020) without a previous MI.
In order to identify the outcome MI-CS, we used the Danish
National Patient Registry to identify all patients with a first-time
hospitalization (as a measure of incidence) with MI [14]. We chose
first-time to create homogenous cohorts. The Danish National
Patient Registry contains data on all hospital admissions since
1977 and on all hospital outpatient specialist clinic and emergency2
room contacts since 1995. Each admission is assigned one primary
diagnosis code and one or more secondary codes classified accord-
ing to the International Classification of Diseases, 8th revision
(ICD-8) until the end of 1993 and 10th revision (ICD-10) thereafter
[14]. We used validated definitions of MI (positive predictive
value: 97%) [15]. The admission with MI had to be at least 24 h,
unless the patients died within first 24 h of admission. This was
done to increase the specificity of the MI diagnosis. We used a par-
tially validated definition of cardiogenic shock: death within first
day of admission, a concurrent diagnosis code of cardiogenic shock
and/or by any medical treatment with vasoactive drugs during the
MI hospitalization [16]. Patients treated with vasoactive drugs, but
without a diagnosis code for cardiogenic shock, were excluded if
they had a diagnosis code for septic shock, hypovolemic shock, or
shock without further specification during the admission. More-
over, if the need for vasoactive drugs only was in relation to a
non-acute coronary artery bypass grafting (CABG) surgery, the
patients was classified as MI without cardiogenic shock. in A flow-
chart of the cohorts is provided in Fig. 1. The cohorts were followed
from date of entry until: MI-CS, death, or end of study periods,
whichever came first.2.3. Covariates
Data on age, sex, and marital status was collected from the Dan-
ish Civil Registration System [13]. We obtained data on previous
comorbidities from the Danish National Patient Registry using both
primary and secondary in- and outpatient diagnosis codes (eTable 1
for ICD-8 and ICD-10 codes). We included congestive heart failure,
peripheral vascular disease, stroke, chronic obstructive lung dis-
ease (COPD), hypertension, atrial fibrillation/flutter, chronic kidney
disease, liver disease, diabetes, and cancer. Validated definitions of
the comorbidities were used [15,17]. Beside a diagnosis codes, dia-
betes was defined by any redeemed prescribed anti-diabetics and
within 180 days before admission, and hypertension by 2 anti-
hypertensive drugs. The Danish National Prescription Registry pro-
vided information on filled preadmission prescriptions within
180 days prior MI admission for beta blockers, calcium channel
blockers, renin-angiotensin-aldosterone system inhibitors, loop-
diuretics, lipid lowering drugs, anti-platelets, anti-coagulants, and
anti-diabetics. Among others, we identified in-hospital procedure
codes of coronary angiography (CAG), percutaneous coronary
intervention (PCI), CABG, thrombolysis, and mechanical circulatory
support from the Danish National Patient Registry. High validity
has been reported for cardiac procedures (98–100%) [15]. All codes
are provided in eTable 1.2.4. Statistical analyses
We characterized patients according to sex, age, comorbidities,
subtypes of MI, concomitant pharmacotherapy, and in-hospital
procedures during lockdown (March 12–May 13, 2020) and in a
corresponding period in 2015–2019 (March 12–May 13), along
with a comparison before and after lockdown within each study
period (before: January 8–March 11, after: March 12–May 13).
Baseline characteristics were described as frequencies and per-
centages or medians with interquartile range as appropriate. Dif-
ferences between periods were tested with use of v2-test for
categorical variables and Kruskal-Wallis test for continuous.
With MI-CS as the numerator and total MI patients as the
denominator, we computed cumulative incidence proportions of
patients with MI-CS in 3-week intervals from January 8/9-May
13, 2015–2019 and January 9–May 13, 2020. Ninety-five percent
confidence intervals were estimated using Clopper-Pearson exact
method.
Fig. 1. Flow chart of study-population. The figure displays the selection of the study population. Abbreviations: CABG: Coronary artery bypass grafting surgery, CS:
Cardiogenic shock, MI: Myocardial infarction. *Patients with vasoactive drugs only in relation to non-acute CABG: 2015: 36, 2016: 31, 2017: 18, 2018: n = 24, 2019: n = 19,
and 2020: n = 29. yPatients excluded due to an ICD-10 code with septic shock, hypovolemic shock, or shock unspecified during MI admission: 2020: n = 2.
Table 1
Baseline characteristics for patients with first-time acute myocardial infarction-
related cardiogenic shock during global lockdown, by calendar period.
2015–2019
March 12–May
13
n (%)
2020
March 12–May
13
n (%)
P
value
Total 342 (100) 60 (100)
Male gender 257 (75) 43 (71) 0.68
Median age, years [IQR] 70 [60–77] 69 [62–76] 0.82
Comorbidities
Heart failure 23 (7) 4 (7) 1.00
Peripheral vascular disease 29 (9) 4 (7) 0.82
Stroke 30 (9) 3 (5) 0.46
Chronic obstructive lung
disease
29 (9) 4 (7) 0.83
Hypertension* 153 (45) 26 (43) 0.95
Atrial fibrillation/flutter 25 (7) 6 (10) 0.65
Chronic kidney disease 29 (9) <3 >0.05
Liver disease 15 (4) 5 (8) 0.33
y
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vals from index date until end of study period. The IR were com-
puted with person years as the denominator and MI-CS as the
numerator. The 3-weeks rates for 2015–2019 were compared with
the 3-week rates in 2020-rates as incidence rate ratios (IRR) using a
Poisson regression model. In addition, we estimated IRRs compar-
ing 2015–2019 with 2020 in complete periods before (January 8/9–
March 11) and after (March 12–May 13) lockdown, respectively.
Lastly, the period before and after lockdown in 2020 was
compared.
We computed 7-day cumulative mortality for MI-CS patients
during lockdown and the corresponding period in 2015–2019 with
use of 1-Kaplan Meier functions. Differences in mortality were
tested with a log-rank test between 2015 and 2019 and 2020
and before and after lockdown in 2020. Crude and adjusted logistic
regression models were created comparing 7-day mortality among
patients with MI-CS during lockdown in 2015–2019 and 2020 and
comparing mortality in 2020 before and after lockdown. In the
adjusted analyses we included: groups of age (<50, 50–59, 60–
69, 70–79, 80<), sex, diabetes, hypertension, and chronic renal dis-
ease. A P value <0.05 was considered statistically significant. The
analyses were performed using SAS version 9.4 and R version 3.5.1.Diabetes 77 (23) 10 (17) 0.40
Cancer 41 (12) 8 (13) 0.94
Subtypes of MI
STEMI 152 (44) 28 (47) 0.86
NSTEMI 59 (17) 9 (15) 0.81
Unspecified 133 (39) 23 (38)
Medication
Beta blockade 75 (22) 10 (17) 0.45
Ca-channel blocker 68 (20) 13 (22) 0.89
RASi 131 (38) 19 (32) 0.402.5. Ethics approval
This study complies with the Declaration of Helsinki. Observa-
tional register studies do not require ethical permission in Den-
mark. The use of data for the study was approved by the Danish
Data Protection Agency (Approval number: P-2019-191).Loop-diuretics 38 (11) 4 (7) 0.42
Lipid lowering drugs 115 (34) 17 (28) 0.51
Anti-platelets 90 (26) 14 (23) 0.58
Anti-coagulants 25 (7) 8 (13) 0.19
Anti-diabetics 64 (19) 9 (15) 0.61
Abbreviations: ADPi: Adenosine diphosphate inhibitor, COPD: Chronic obstructive
pulmonary disease, IQR: Inter quartile range, NSTEMI: Non-ST segment elevation
myocardial infarction, STEMI: ST segment elevation myocardial infarction, RASi:
Renin-angiotensin system inhibitor.
* Defined as redemption of 2 antihypertensive drugs 180 days before MI
admission.
y Defined as an ICD-10 code with diabetes or any redeemed prescribed anti-dia-
betic drug 180 days before MI admission.
 Anti-platelets: Aspirin, adenosine-di-phosphate inhibitors, dipyridamole.3. Results
3.1. Patients characteristics
We identified 11,769 first-time MI patients in the study period
2015–2019 of whom 696 (5.9%) had cardiogenic shock (Fig. 1). In
comparison, 2132 first time MI patients were identified in the
2020-period of whom 119 had cardiogenic shock (5.6%). No differ-
ences were observed concerning age, sex, co-morbidities, subtypes
of MI, or prior prescribed medication between patients with MI-CS
during lockdown in 2015–2019 and 2020 (Table 1). The baseline3
characteristics were also similar in in periods before and after lock-
down in 2015–2019 and 2020, respectively (eTable 2).
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The total number of MI patients decreased with 15% during
lockdown comparing the average number of MI admission in
2015–2019 (n = 1171) with the number of MI in 2020 (n = 996).
The incidence proportions of MI-CS were similar during lockdown
comparing 2015–2019 and 2020 (5.8% (95% CI: 5.2–6.5) vs. 5.9%
(95% CI: 4.6–7.6)), and no difference was observed over time in
the 2015–2019 and 2020 periods (Fig. 2). The total number of
patients with MI-CS, person years, and the following IR in 3-
week intervals are presented in Fig. 3 (eTable 3). No differences
in IR over time was observed comparing 2015–2019 and 2020.
The IR per 100,000 person years in 2015–2019 before lockdown
(January 8–March 11) was 9.2 (95% CI: 8.3–10.2) and after lock-
down (March 12–May 13) 8.9 (95% CI: 8.0–9.9). In 2020, the IRs
before and after lockdown were 7.5 (95% CI: 5.8–9.7) and 7.7
(95% CI:6.0–9.9). In the regression analyses, the corresponding IRRs
were 0.81 (95% CI: 0.0.59–1.12) and 0.87 (95% CI: 0.57–1.32) for
periods before and after lockdown comparing 2020 with 2015–
2019. The IRRs for the complete period from 8 January through
May 13 per 3-week comparing 2020 with 2015–2019 are displayed
in Fig. 4. The IRR comparing before and after lockdown in 2020 was
1.02 (95% CI: 0.74–1.41).3.3. Seven-day mortality during national lockdown
In unadjusted analyses, we observed a higher 7-day mortality
during lockdown in 2020 compared with 2015–2019 (45% (95%
CI: 32–58) vs. 36%, (95% CI: 31–41)) and the same was observed
comparing the periods before and after lockdown in 2020 (34%
(95% CI: 22–46) vs. 45% (95% CI: 32–58). However, in the age,
sex, and comorbidity adjusted analysis comparing 2020 with
2015–2019 during lockdown the mortality was similar (OR: 1.04Fig. 2. Cumulative incidence proportions of MI-CS, by study years. The figure presents th
21st days from January 8–May 13, 2015–2019 and January 9–May 13, 2020. MICS: Myo
4
(95% CI: 0.68–1.59), and the same result was seen in the analysis
comparing before and after lockdown in 2020 (OR: 1.56 (95% CI:
0.76–3.34)).
3.4. In-hospital procedures
The proportion of patients who underwent CAG, PCI, CABG, and
extra corporeal membrane oxygenation (ECMO) were similar
between 2015 and 2019 and 2020 during lockdown (p > 0.05)
(Table 2). Although limited by small numbers, the use of left ven-
tricular assist device seemed lower in 2020 compared with
2015–2020 during lockdown, however, it did not differ before
and after lockdown in 2020 (eTable 4). The use of thrombolysis
was non-existent in all three years, along with the use of intra-
aortic balloon pump (IABP). The results were similar comparing
the periods before and after lockdown in 2020 (eTable 4).4. Discussion
Despite a decrease in MI overall, the incidence of MI-CS was not
associated with the national lockdown during the COVID-19 era
compared with a corresponding calendar period from 2015 to
2019. The 7-day mortality and in-hospital procedures in patients
with MI-CS were similar between the 2015–2019 period and the
2020-period, and before and after lockdown in 2020.
On February 27 the first Danish citizen was diagnosed with
COVID-19, and on March 11 the national government introduced
nationwide lockdown of the Danish society with closed schools,
day-cares, public workplaces, social distancing, and March 15 the
borders were closed. Along with these initiatives in order to limit
the infection of the COVID-19, the health care system was reorga-
nized to obtain resources for the management of COVID-19
patients. Non-essential visits were postponed, and emergencye cumulative incidence proportion of first time MI-CS of the total number of MI per
cardial infarction-related cardiogenic shock.
Fig. 3. Incidence rates as numbers of MI-CS per 100,000 person years, by study years. displays the incidence rates of MI-CS per 21st days from January 8–May 13, 2015–2019
and January 9–May 13, 2020. MICS: Myocardial infarction-related cardiogenic shock.
Fig. 4. Incidence rate ratios of MI-CS in 2020 compared with 2015–2019. The figure shows the incidence rate ratios per 21st days in 2020 compared with 2015–2019. MICS:
Myocardial infarction-related cardiogenic shock.
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Table 2
In-hospital procedures in myocardial infarction-related cardiogenic shock during
national lockdown, by calendar period.
2015–2019
March 12–May
13
n (%)
2020
March 12–May
13
n (%)
P
value
Total 342 (100) 60 (100)
Revascularization
Coronary angiography 239 (70) 43 (72) 0.91
PCI 208 (61) 37 (62) 1.0
CABG 23 (7) 4 (7) 1.0
Thrombolysis <3 0 (0.0) >0.05
Mechanical circulatory
support
IABP* <3 0 (0.0) >0.05-
Left ventricular assist
device
44 (13) <3 <0.05
ECMO 26 (8) 4 (7) 1.0
Intensive care
Renal replacement therapy 48 (14) 8 (13) 1.0
Mechanical ventilation 261 (76) 38 (63) 0.05
Abbreviations: CABG: Coronary artery bypass grafting surgery, ECMO: Extra cor-
poreal membrane oxygenation, IABP: Intra-aortic balloon pump, PCI: Percutaneous
coronary intervention.
* Due to the data permissions we are not allowed to report <3 observation.
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the resources in the health care systems was enough, and espe-
cially were the intensive care units never near maximum capacity.
It was speculated that the increased level of physiological stress
could lead to an increase in MI [18], along with increased risk of
viral induced MI[19] and peri-myocarditis mimicking the course
of an MI [20,21]. In addition, recent reports indicated that
COVID-19 infection was associated with increased thromboem-
bolic risk [22], hereunder myocardial infarction, which would
affect MI incidence further during the COVID-19 pandemic. Never-
theless, a 30–40% reduction in the incidence of MI was observed
worldwide by reports from the U.S, Spain, Denmark, Italy and Hong
Kong [1–4,6]. The decrease was observed for both patients with
STEMI and NSTEMI with the largest decrease among patients with
NSTEMI [4].
In addition, a recent single centre study from study from Hong
Kong observed a marked delay in the time from symptom onset
until seeking medical aid among 7 ST-segment elevation myocar-
dial infarction patients emphasizing the changed behaviour among
MI patients [5]. Due to potential missed or delayed diagnosis and
treatment of MI, one would expect more extensive myocardial
damage with more compromised hemodynamic status, and thus
higher risk of cardiogenic shock and mortality, among MI patients
during the COVID-19 pandemic. Based on data from a single ter-
tiary cardiac centre in Hong Kong limited by a few number of
observations (n = 149), the cumulative incidence proportion of
MI-CS before and after the outbreak of COVID-19 did not differ
(8% vs. 13%, p = 0.42) [6]. In a multicentre Italian study with data
from intensive care units, the rate of MI with severe complications,
including MI-CS, increased in the first week after lockdown [4]. The
incidence of cardiogenic shock in both the 2015–2019 and 2020-
period in this study was consistent with previous studies (3–7%)
[7,8,23,24], and current observations suggest a decreasing trend
in MI-CS incidence during latest years [7,9,23]. The incidence pro-
portions of MI-CS in 2019 and 2020 was lower compared with pre-
vious years, however, no consistent trend in MI-CS incidence was
observed. Still, we observed no difference in the incidence of MI-
CS during national lockdown in 2020 compared with incidence of
cardiogenic shock before lockdown in 2020 or compared with a
corresponding calendar period 2015–2019, despite the decrease
in MI overall. Neither was any difference in subtypes of MI, e.g.6
STEMI and NSTEMI, observed comparing lockdown with non-
lockdown.
Based on the marked reduction in incidence of MI during
COVID-19 pandemic [1–4,6], we hypothesized that the incidence
of MI-CS would increase as a result of missed or delayed treatment,
thus, prolonged ischemia and progressively left-ventricular dys-
function. A concern exists whether the unaffected incidence of
MI-CS could be due to misdiagnosis of cardiogenic shock when
all focus is diverted towards the COVID-19 disease [11]. Cardiovas-
cular manifestations of COVID-19 is acute heart failure, myocardi-
tis, arrythmias, and elevated troponins, and along with severe
systemic inflammation, multi-organ dysfunction, and acute respi-
ratory distress this course mimics MI-CS [21].
In a recent study from Hong Kong comparing patients with MI
before and after COVID-19 outbreak, no difference in MI-related
in-hospital mortality was observed (6% vs 13%. P = 0.24) [6]. How-
ever, the results were based on a limited number of observations.
On the contrary, an Italian study observed a marked increase in
MI mortality comparing one week after lockdown in 2020 with
2019 (relative risk: 3.6 (2.0–6.4)) [4]. In this study, 7-day absolute
mortality in patients with MI-CS was higher in the lockdown per-
iod compared before lockdown in 2020 and the corresponding per-
iod in 2015–2019. However, the results were similar in the 2015–
2019 period and the 2020-period when age, sex, and comorbidities
were accounted for. Few studies reported 7-day mortality, how-
ever, the results of this study are comparable with current evi-
dence [7,9,23,25].
As a result of the decrease in MI, a recent study reported a 40%
reduction in PCI procedures and a small increase in use of throm-
bolysis among MI patients [1]. During the COVID-19 pandemic, the
early revascularization remains the standard recommendations for
the treatment of acute MI whenever possible [10,26]. The manage-
ment of patients with MI-CS was similar in the 2020-period com-
pared with the 2015–2019-period, and the proportion of patients
with MI and cardiogenic shock who underwent CAG and PCI were
consistent with previous reporting from MI-CS cohorts [7,9,23,27].
We have no knowledge on potential delays from symptom onset to
medical contact or in-hospital timing of revascularization in this
study.
4.1. Strengths and limitations
The study data were obtained from nationwide registries in a
country with universal and free tax-supported access to health
care, unaffected by socioeconomic status or insurance, thus, mini-
mizing the potential of selection bias [12]. Moreover, the registries
provide complete and long-term follow-up [13]. The diagnosis
codes for MI, CS, comorbidities, and the procedure code of
inotropes/vasopressors have been validated with high positive pre-
dictive values [15–17].
Due to the definition of CS based upon need for inotropes/vaso-
pressors in MI patients, we cannot exclude misclassification of
pressor-stabilized OHCA patients without manifest CS in the study
population. However, at time of hospital arrival these patients pre-
sent with similar clinical parameters [28] and therefore immediate
indistinguishable, why the results of this study reflect the real life
setting.
We cannot exclude unmeasured or residual confounding due to
the observational design. Uncomplicated cases of hypertension and
diabetes are treated only by general practitioners and we may lack
completeness of these data; though, we sought to increase com-
pleteness of diabetes by adding information on filled prescriptions
for anti-diabetic drugs. Additionally, we lacked clinical data such as
lactate levels, creatinine clearance, ejection fraction, out-of-
hospital-cardiac-arrest status, in addition to complete data on sub-
types of MI (STEMI and NSTEMI).
M.D. Lauridsen, J.H. Butt, L. Østergaard et al. IJC Heart & Vasculature 31 (2020) 1006595. Clinical perspectives
A concern exists whether the delay in treatment and decrease in
incidence of acute MI have led to increased mortality and morbid-
ity, however, this study did not observe any differences in inci-
dence of cardiogenic shock during the COVID-19 pandemic
compared with the 2015–2019 period. The results of this study
may be generalizable to other Western countries with similar
health care system and guideline-based approach to the manage-
ment of MI-CS. However, it must be emphasized, that Denmark
was a low incidence COVID-19 country, and the Danish health care
system was not at any time in threat of break down. In the blur of
the COVID-19 pandemic, the modern health care system needs to
continuously detect and treat other acute medical conditions.6. Conclusion
We could not identify a significant association of the national
lockdown on the incidence of MI with cardiogenic shock, along
with similar in-hospital management and mortality in patients
with MI and cardiogenic shock before and after lockdown. Our
study does not support the fear that the reduction in MI incidence
during the pandemic lockdown translates into worse cases of MI in
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